166 related articles for article (PubMed ID: 34802718)
1. [Complications other than infections, CRS and ICANS following CAR T-cells therapy: Recommendations of the Francophone Society of bone marrow transplantation and cell therapy (SFGM-TC)].
Pochon C; Courbon C; Bay JO; Moreau AS; Paul F; Picard M; Sterin A; Tudesq JJ; Vicente C; Yakoub-Agha M; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S98-S103. PubMed ID: 34802718
[TBL] [Abstract][Full Text] [Related]
2. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
3. [Prevention and management of infections in patients undergoing CAR T-cell therapy: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Paul F; Vicente C; Courbon C; Moreau AS; Picard M; Pochon C; Sterin A; Tudesq JJ; Yakoub-Agha M; Bay JO; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S90-S97. PubMed ID: 34876272
[TBL] [Abstract][Full Text] [Related]
4. [Management of neurotoxicity following CAR-T cell therapy: Recommendations of the SFGM-TC].
Picard M; Sterin A; Bay JO; Courbon C; Moreau AS; Paul F; Pochon C; Tudesq JJ; Vicente C; Yakoub-Agha M; Yakoub-Agha I
Bull Cancer; 2023 Feb; 110(2S):S123-S131. PubMed ID: 35094839
[TBL] [Abstract][Full Text] [Related]
5. [Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC].
Tudesq JJ; Yakoub-Agha M; Bay JO; Courbon C; Paul F; Picard M; Pochon C; Sterin A; Vicente C; Canet E; Yakoub-Agha I; Moreau AS
Bull Cancer; 2023 Feb; 110(2S):S116-S122. PubMed ID: 34895696
[TBL] [Abstract][Full Text] [Related]
6. Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Yakoub-Agha I
Curr Res Transl Med; 2018 May; 66(2):57-58. PubMed ID: 29685843
[TBL] [Abstract][Full Text] [Related]
7. [Follow-up logbook of patients receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Berquier M; Cherel L; Clerc Renaud D; Hospital Gustems C; Wallart Brejaud A; Yakoub-Agha I; Beauvais D
Bull Cancer; 2021 Dec; 108(12S):S39-S44. PubMed ID: 33992416
[TBL] [Abstract][Full Text] [Related]
8. [Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Rubio MT; Varlet P; Allain V; Ballot C; Cuffel A; Deschamps M; Ferrand C; Foguenne J; Forcade E; Huynh A; Guihot A; Latouche JB; Lemarie C; Martinroche G; Morin F; Nguyen S; Schmit K; Servais S; Simonetta F; Yakoub-Agha I; Caillat Zucman S
Bull Cancer; 2021 Dec; 108(12S):S53-S64. PubMed ID: 34253335
[TBL] [Abstract][Full Text] [Related]
9. [Quality assessment of CAR T-cell activity: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Duléry R; Lacassagne MN; Giraud C; Ader V; Beaumont JL; Carnoy S; Carpentier A; Fegueux N; Gibault-Joffe C; Guerout-Verite MA; Huynh TNP; Lewalle P; Perrin A; Plaza-Milhe S; Bonnin A; Yakoub-Agha I; Contentin N
Bull Cancer; 2020 Dec; 107(12S):S193-S201. PubMed ID: 33187683
[TBL] [Abstract][Full Text] [Related]
10. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.
Gutgarts V; Jain T; Zheng J; Maloy MA; Ruiz JD; Pennisi M; Jaimes EA; Perales MA; Sathick J
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1071-1076. PubMed ID: 32088364
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
12. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J; Tan Y; Wang G; Deng B; Ling Z; Song W; Seery S; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Yuan Y; Yan F; Tian Z; Tang K; Zhang J; Chang AH; Feng X
J Clin Oncol; 2021 Oct; 39(30):3340-3351. PubMed ID: 34324392
[TBL] [Abstract][Full Text] [Related]
13. [Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC)].
Yakoub-Agha I; Moreau AS; Ahmad I; Borel C; Hadhoum N; Masouridi-Levrat S; Naudin J; Nicolas-Virelizier E; Ouachée-Chardin M; Platon L; Quessar A; Roth-Guepin G; Beauvais D; Baruchel A; Cornillon J
Bull Cancer; 2019 Jan; 106(1S):S102-S109. PubMed ID: 30661749
[TBL] [Abstract][Full Text] [Related]
14. [A standardized medical report template for CAR T-Cell therapy patients: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Broussais F; Vasseur A; Karam M; Chaillou D; Pereira M; Yakoub-Agha I; Raus N
Bull Cancer; 2021 Dec; 108(12S):S82-S86. PubMed ID: 33933288
[TBL] [Abstract][Full Text] [Related]
15. The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy.
Mansouri V; Yazdanpanah N; Rezaei N
Int Rev Immunol; 2022; 41(6):649-668. PubMed ID: 34607523
[TBL] [Abstract][Full Text] [Related]
16. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.
Zhou H; Yang M; Cui L; Jiang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107072. PubMed ID: 33059198
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cell toxicity.
Baymon DE; Boyer EW
Curr Opin Pediatr; 2019 Apr; 31(2):251-255. PubMed ID: 30762706
[TBL] [Abstract][Full Text] [Related]
19. [Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Aubrun C; Bay JO; Beguin Y; Bigenwald C; Brissot E; Chalandon Y; Chevallier P; Pagliuca S; Magro L; Srour M
Bull Cancer; 2024 Apr; ():. PubMed ID: 38631984
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T-cell therapy: An emergency medicine focused review.
Long B; Yoo MJ; Brady WJ; Holian A; Sudhir A; Gottlieb M
Am J Emerg Med; 2021 Dec; 50():369-375. PubMed ID: 34461398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
